We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Preventive Surgery Cost-Effective in Lynch Syndrome

By HospiMedica staff writers
Posted on 03 Apr 2007
Prophylactic surgery is both cost-effective and the best treatment for women at risk of endometrial and ovarian cancer due to Lynch syndrome, according to a new study.

Researchers at the University of California at San Francisco (UCSF; USA) developed a mathematic cost model that showed that risk-reducing surgery--hysterectomy with bilateral salpingo-oophorectomy--was more cost-effective than annual screening or routine annual check-ups. More...
The researchers used the Surveillance, Epidemiology and End Results (SEER) database from 1988 to 2001 to estimate mortality and data from UCSF to estimate the costs of care.

The cost model included such factors as screening charges, hospital stays, chemotherapy and radiation, surgery, home health care, and several other factors. Results showed that the cumulative cost of endometrial cancer would be about US$113,000 if the patients died five years after diagnosis, $194,000 if she died 10 years after diagnosis. Even if treatment was successful and the woman was cured, the cost would be about $146,000.
In contrast, the researchers estimated the cost of preventive surgery to be about $11,000.

The researchers expressed their cost-effectiveness findings using discounted life-years, which are a statistical method of standardizing patients' perception of the value of an intervention in terms of life expectancy. On that basis, preventive surgery has a cost per discounted life-year of $954, compared with $2,406 for annual screening and $3,319 for annual check-ups. The study was presented at the Society of Gynecologic Oncologists annual meeting, held in San Diego (CA, USA) during March 2007.

"Over a lifetime, annual screening was about 2.5 times as expensive as preventive surgery at age 30, and routine check-ups were about 3.5 times as expensive,” said lead author Lee-May Chen, M.D. "A combination of colectomy, hysterectomy, and bilateral salpingo-oophorectomy would provide a lot of peace of mind. If you've eliminated [the risk of] colon cancer, endometrial cancer, and ovarian cancer, you've eliminated the top three.”

Lynch syndrome--also known as hereditary non-polyposis colorectal cancer--affects one woman in 2,000. Women with the syndrome have a lifetime risk of endometrial cancer that is in the range of 40-60%, compared with 2% in the general population. At the same time, their risk of ovarian cancer ranges from 5%-12%, compared with between 1% and 2% in the general population.


Related Links:
University of California at San Francisco

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.